Canada: Pharma In Brief - Federal Court Addresses The Relationship Between Prohibition Applications And Infringement/Impeachment Actions

Case: Bayer Inc. v Cobalt Pharmaceuticals Company, 2016 FC 1013 (Court Files No. T-1379-13, T-1468-13, and T-1368-14)

Drug: By Bayer Inc.: YAZ (3.0 mg drospirenone and 0.020 mg ethinyl estradiol tablets) and YASMIN (3.0 mg drospirenone and 0.030 mg ethinyl estradiol tablets) 

By Apotex Inc. (Apotex): MYA (3.0 mg drospirenone and 0.020 mg ethinyl estradiol tablets) and ZAMINE 21 & ZAMINE 28 (ZAMINE) (3.0 mg drospirenone and 0.030 mg ethinyl estradiol tablets) 

By Cobalt Pharmaceuticals Company (Cobalt): ZARAH 21 & ZARAH 28 (ZARAH) (3.0 mg drospirenone and 0.030 mg ethinyl estradiol tablets)

Nature of case: Liability phase of bifurcated action for patent infringement and impeachment pursuant to the Patent Act, RSC 1985, c P-4

Successful party: Bayer Inc. & Bayer Pharma Aktiengesellschaft (collectively Bayer)

Date of decision: September 7, 2016 

Summary

This action concerns Bayer's Canadian Patent No. 2,382,426 (the '426 Patent) and generic versions of two combination oral contraceptives marketed in Canada by Bayer: YAZ and YASMIN, both of which contain drospirenone and ethinyl estradiol.

The court found that the '426 Patent was valid, rejecting attacks on the bases of obviousness, anticipation, overbreadth, insufficiency, ambiguity, and inutility. The court also found that all of the alleged generic products infringed the asserted claims of the '426 Patent. Quantification will be determined in a subsequent proceeding.
 

Background

Both Apotex and Cobalt (now Actavis, itself recently acquired by Teva) market generic versions of YASMIN, known respectively as ZAMINE and ZARAH. Apotex also markets a generic version of YAZ, known as MYA. As we reported here and here, in proceedings under the Patented Medicines (Notice of Compliance) Regulations (the Regulations), Bayer succeeded in preventing Cobalt from marketing a proposed generic version of YAZ. It failed to do so in respect of Apotex's generic YAZ product, which is marketed as MYA. Bayer sued Apotex and Cobalt for infringement; Apotex and Cobalt counterclaimed for a declaration of invalidity.

The '426 Patent is not listed against YASMIN; both Apotex and Cobalt were able to obtain NOCs for their generic versions of this product.

The court held that the claimed invention of asserted claims of the '426 Patent is rapidly dissolving oral formulations of drospirenone particles and ethinyl estradiol. These formulations exhibit surprisingly good bioavailability as a contraceptive despite being exposed directly to the gastric environment.
 

Preliminary issues: the precedential value of prohibition applications and expert blinding

Precedential value of prohibition applications in a subsequent action. Having twice litigated the construction and validity of the '426 Patent in prohibition applications, Bayer argued that the court should adopt the findings of the Federal Court of Appeal and Federal Court on these issues. Cobalt submitted that although the construction reached in the prohibition applications could be persuasive, the court was free to depart from findings made under the Regulations because of the broader evidentiary scope of an action. Apotex also acknowledged that the Court of Appeal's judgments on questions of law may be persuasive, but argued that findings made under the Regulations should have no bearing on this action.

The court held that as a question of law, the Court of Appeal's findings regarding claims construction — including determination of the inventive concept and promised utility — are prima facie binding but can be revisited if warranted by the evidence. Conversely, the court held that findings of fact, or mixed fact and law, are potentially persuasive but do not require judicial comity and must be approached with caution. This includes findings on obviousness, ambiguity, overbreadth, utility, and insufficiency.

Expert blinding. The court held that although "blinding" has recently found some favour, it is not a principle of law that applies in all cases. The main concern is the substance and reasoning of the expert's opinion. As a result, when issues of credibility arise, blinding may be persuasive, but is no guarantee of reliability. A well-supported but unblinded opinion needn't be given less weight. Blinding was not a significant factor in the court's decision in this case.
 

The asserted claims of the '426 Patent are valid

Obviousness. The court held that there was no good reason to depart from the construction of the inventive concept previously upheld by the Court of Appeal under the Regulations. Justice Fothergill was persuaded by the inventors' course of conduct, as well as the absence of any similar product prior to the '426 Patent, that while a skilled person may have been curious about whether such a formulation would work, the testing required to answer that question was "worth a try" — not obvious to try.

Anticipation. Apotex argued that the asserted claims were anticipated by Bayer's own clinical studies. Justice Fothergill agreed with Bayer that these trials were not disclosures: while there was a theoretical possibility that one or more tablets may have found their way into the hands of the skilled person, inventive insight would have been required to reverse-engineer the invention. The court also held that if disclosure has been made out, the claims would have nonetheless been saved under the experimental-use exception to anticipation.

Overbreadth. Apotex argued that the research conducted by the inventors of the '426 Patent was limited to only one method of obtaining a rapid drospirenone dissolution profile, whereas the asserted claims monopolized all manners of achieving that end. Apotex also argued that these claims are overbroad to the extent that they do not require exposure of the formulation to the gastric environment upon dissolution. Justice Fothergill adopted the reasons of the Court of Appeal on this issue, concluding that the patent teaches the solution to a problem and embraces all drospirenone particles that achieve that solution.

Insufficiency & ambiguity. Apotex's insufficiency and ambiguity arguments arose from the fact that the asserted claims specify a drospirenone dissolution profile described in the specification for a tablet dosage form containing 3 mg of drospirenone, yet the claims included any amount of drospirenone from about 2 to about 4 mg. Apotex asserted that a means of achieving the specified dissolution profile at strengths other than 3 mg was not provided. Justice Fothergill rejected Apotex's argument, holding that a skilled person could have scaled or otherwise adapted the instructions to obtain the desired dissolution profile without resort to inventive means.

Inutility.
As a matter of judicial comity, the court adopted the promised utility found by Hughes J under the Regulations and was satisfied that this promise was demonstrated or soundly predicted by two examples in the specification of the '426 Patent.
 

The asserted claims of the '426 Patent are infringed

The court analyzed the infringement issues raised by Apotex and Cobalt separately.

Infringement by Apotex: ZAMINE and MYA. The sole issue regarding infringement by Apotex was whether ZAMINE and MYA tablets contain at least 2 mg of drospirenone particles. Apotex argued that these products contained a "molecular dispersion" of drospirenone, which is sufficiently dissolved that it no longer constitutes "particles." Bayer obtained samples of the Apotex tablets and used Raman spectroscopy to determine whether they contained drospirenone particles. Apotex countered this testing with infrared spectroscopy and replication of Bayer's testing.

The court found the testing evidence credible but was critical of experts for both sides regarding their difficulty explaining the results of some of their analytical techniques. Although Bayer abandoned part of its evidence for this reason and despite myriad attacks on the adequacy of its experiments, Bayer nonetheless succeeded in showing that Apotex's products infringe the asserted claims.

Infringement by Cobalt: ZARAH. Before trial, Cobalt unsuccessfully moved to amend its pleading to delete a reference to drospirenone particles in ZARAH and sought to plead instead that the product does not contain drospirenone particles. Justice Fothergill considered this pleading to be a formal admission that at least some of the drospirenone in ZARAH is in particle form, with the result that Cobalt was limited to disputing the proportion of particulate drospirenone present. Both Bayer and Cobalt used Raman spectroscopy to examine this issue.

Justice Fothergill accepted that Cobalt's manufacturing process necessarily produces drospirenone particles and that at least 90% of the drospirenone in its tablets was present in this form. As a result, Bayer's infringement argument was successful.

Relief & bifurcation. The court awarded Bayer a declaration of validity in respect of the asserted claims and injunctive relief against Apotex and Cobalt, as well as the delivery-up or destruction of infringing tablets. The parties were given 30 days to make submissions on Bayer's entitlement to claim its damages or an accounting of profits. The quantification of Bayer's monetary compensation for infringement is bifurcated and will be determined in a subsequent proceeding.
 

Appeal

Apotex and Cobalt have both appealed from the court's judgment (see Court Files No. A-314-16 and A-318-16, respectively).  

Links:

This decision: Bayer Inc. v Cobalt Pharmaceuticals Company, 2016 FC 1013

Previous prohibition applications: 


About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world nortonrosefulbright.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.